CD3E and prostate carcinoma: Other drugs classified as IO included an adenosine receptor antagonist, an indoleamine‐pyrrole 2,3‐dioxygenase inhibitor, two oncolytic viruses and a bispecific antibody targeting CD3ε on T‐cells and prostate‐specific membrane antigen in refractory prostate cancer.